{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:25:30Z","timestamp":1648632330201},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00115-019-00788-w","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T07:03:28Z","timestamp":1569567808000},"page":"995-1004","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update antithrombotische Sekund\u00e4rprophylaxe des isch\u00e4mischen Schlaganfalls"],"prefix":"10.1007","volume":"90","author":[{"given":"Martin","family":"K\u00f6hrmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"788_CR1","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt\u00a0DL, Fox\u00a0KA, Hacke\u00a0W, Berger\u00a0PB, Black\u00a0HR, Boden\u00a0WE et\u00a0al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N\u00a0Engl J Med 354:1706\u20131717","journal-title":"N Engl J Med"},{"key":"788_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","volume":"364","author":"HC Diener","year":"2004","unstructured":"Diener\u00a0HC, Bogousslavsky\u00a0J, Brass\u00a0LM, Cimminiello\u00a0C, Csiba\u00a0L, Kaste\u00a0M et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364:331\u2013337","journal-title":"Lancet"},{"key":"788_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1056\/NEJMoa1204133","volume":"367","author":"The SPS3 Investigators","year":"2012","unstructured":"The SPS3 Investigators (2012) Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N\u00a0Engl J Med 367:817\u2013825","journal-title":"N Engl J Med"},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston\u00a0SC, Amarenco\u00a0P, Albers\u00a0GW, Denison\u00a0H, Easton\u00a0JD, Evans\u00a0SR et\u00a0al (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N\u00a0Engl J Med 375:35\u201343","journal-title":"N Engl J Med"},{"key":"788_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston\u00a0SC, Easton\u00a0JD, Farrant\u00a0M, Barsan\u00a0W, Conwit\u00a0RA, Elm\u00a0JJ et al (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N\u00a0Engl J Med 379:215\u2013225","journal-title":"N Engl J Med"},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy\u00a0J, Hill\u00a0MD, Ryckborst\u00a0KJ, Eliasziw\u00a0M, Demchuk\u00a0AM, Buchan\u00a0AM et\u00a0al (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A\u00a0randomised controlled pilot trial. Lancet Neurol 6:961\u2013969","journal-title":"Lancet Neurol"},{"key":"788_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang\u00a0Y, Wang\u00a0Y, Zhao\u00a0X, Liu\u00a0L, Wang\u00a0D, Wang\u00a0C et\u00a0al (2013) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N\u00a0Engl J Med 369:11\u201319","journal-title":"N Engl J Med"},{"key":"788_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1474-4422(17)30038-8","volume":"16","author":"P Amarenco","year":"2017","unstructured":"Amarenco\u00a0P, Albers\u00a0GW, Denison\u00a0H, Easton\u00a0JD, Evans\u00a0SR, Held\u00a0P et al (2017) Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: A subgroup analysis of SOCRATES, a\u00a0randomised, double-blind, controlled trial. Lancet Neurol 16:301\u2013310","journal-title":"Lancet Neurol"},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0000000000001844","volume":"85","author":"X Wang","year":"2015","unstructured":"Wang\u00a0X, Zhao\u00a0X, Johnston\u00a0SC, Xian\u00a0Y, Hu\u00a0B, Wang\u00a0C et\u00a0al (2015) Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. Neurology 85:573\u2013579","journal-title":"Neurology"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","volume":"132","author":"Y Wang","year":"2015","unstructured":"Wang\u00a0Y, Pan\u00a0Y, Zhao\u00a0X, Li\u00a0H, Wang\u00a0D, Johnston\u00a0SC et al (2015) Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: One-year outcomes. Circulation 132:40\u201346","journal-title":"Circulation"},{"key":"788_CR11","doi-asserted-by":"publisher","first-page":"k5108","DOI":"10.1136\/bmj.k5108","volume":"363","author":"Q Hao","year":"2018","unstructured":"Hao\u00a0Q, Tampi\u00a0M, O\u2019Donnell\u00a0M, Foroutan\u00a0F, Siemieniuk\u00a0RA, Guyatt\u00a0G (2018) Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: Systematic review and meta-analysis. BMJ 363:k5108","journal-title":"BMJ"},{"key":"788_CR12","doi-asserted-by":"publisher","first-page":"k5130","DOI":"10.1136\/bmj.k5130","volume":"363","author":"K Prasad","year":"2018","unstructured":"Prasad\u00a0K, Siemieniuk\u00a0R, Hao\u00a0Q, Guyatt\u00a0G, O\u2019Donnell\u00a0M, Lytvyn\u00a0L et\u00a0al (2018) Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: A\u00a0clinical practice guideline. BMJ 363:k5130","journal-title":"BMJ"},{"key":"788_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019830307","author":"SC Johnston","year":"2019","unstructured":"Johnston\u00a0SC, Amarenco\u00a0P, Denison\u00a0H, Evans\u00a0SR, Himmelmann\u00a0A, James\u00a0S et\u00a0al (2019) The acute stroke or transient ischemic attack treated with ticagrelor and aspirin for prevention of stroke and death (THALES) trial: Rationale and design. Int J Stroke. \nhttps:\/\/doi.org\/10.1177\/1747493019830307","journal-title":"Int J Stroke"},{"key":"788_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.410420606","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","unstructured":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857\u2013865","journal-title":"Ann Neurol"},{"key":"788_CR15","doi-asserted-by":"publisher","first-page":"CD001342","DOI":"10.1002\/14651858.CD001342.pub3","volume":"9","author":"EL De Schryver","year":"2012","unstructured":"De Schryver\u00a0EL, Algra\u00a0A, Kappelle\u00a0LJ, van Gijn\u00a0J, Koudstaal\u00a0PJ (2012) Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 9:CD1342. \nhttps:\/\/doi.org\/10.1002\/14651858.CD001342.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1474-4422(06)70685-8","volume":"6","author":"A Algra","year":"2007","unstructured":"Algra\u00a0A (2007) Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. Lancet Neurol 6:115\u2013124","journal-title":"Lancet Neurol"},{"key":"788_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr\u00a0JP, Thompson\u00a0JL, Lazar\u00a0RM, Levin\u00a0B, Sacco\u00a0RL, Furie\u00a0KL et\u00a0al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N\u00a0Engl J Med 345:1444\u20131451","journal-title":"N Engl J Med"},{"key":"788_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly\u00a0SJ, Eikelboom\u00a0J, Joyner\u00a0C, Diener\u00a0HC, Hart\u00a0R, Golitsyn\u00a0S et\u00a0al (2011) Apixaban in patients with atrial fibrillation. N\u00a0Engl J Med 364:806\u2013817","journal-title":"N Engl J Med"},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","volume":"11","author":"HC Diener","year":"2012","unstructured":"Diener\u00a0HC, Eikelboom\u00a0J, Connolly\u00a0SJ, Joyner\u00a0CD, Hart\u00a0RG, Lip\u00a0GY et\u00a0al (2012) Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A\u00a0predefined subgroup analysis from AVERROES, a\u00a0randomised trial. Lancet Neurol 11:225\u2013231","journal-title":"Lancet Neurol"},{"key":"788_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","volume":"13","author":"RG Hart","year":"2014","unstructured":"Hart\u00a0RG, Diener\u00a0HC, Coutts\u00a0SB, Easton\u00a0JD, Granger\u00a0CB, O\u2019Donnell\u00a0MJ et\u00a0al (2014) Embolic strokes of undetermined source: The case for a\u00a0new clinical construct. Lancet Neurol 13:429\u2013438","journal-title":"Lancet Neurol"},{"key":"788_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"HC Diener","year":"2019","unstructured":"Diener\u00a0HC, Sacco\u00a0RL, Easton\u00a0JD, Granger\u00a0CB, Bernstein\u00a0RA, Uchiyama\u00a0S et\u00a0al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N\u00a0Engl J Med 380:1906\u20131917","journal-title":"N Engl J Med"},{"key":"788_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","volume":"378","author":"RG Hart","year":"2018","unstructured":"Hart\u00a0RG, Sharma\u00a0M, Mundl\u00a0H, Kasner\u00a0SE, Bangdiwala\u00a0SI, Berkowitz\u00a0SD et\u00a0al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N\u00a0Engl J Med 378:2191\u20132201","journal-title":"N Engl J Med"},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel\u00a0MR, Mahaffey\u00a0KW, Garg\u00a0J, Pan\u00a0G, Singer\u00a0DE, Hacke\u00a0W et\u00a0al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N\u00a0Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","volume":"17","author":"SE Kasner","year":"2018","unstructured":"Kasner\u00a0SE, Swaminathan\u00a0B, Lavados\u00a0P, Sharma\u00a0M, Muir\u00a0K, Veltkamp\u00a0R et\u00a0al (2018) Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: A\u00a0prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 17:1053\u20131060","journal-title":"Lancet Neurol"},{"issue":"7","key":"788_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamaneurol.2019.0617","volume":"76","author":"JS Healey","year":"2019","unstructured":"Healey\u00a0JS, Gladstone\u00a0DJ, Swaminathan\u00a0B, Eckstein\u00a0J, Mundl\u00a0H, Epstein\u00a0AE et\u00a0al (2019) Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: Secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 76(7):764\u2013773. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2019.0617","journal-title":"JAMA Neurol"},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly\u00a0SJ, Ezekowitz\u00a0MD, Yusuf\u00a0S, Eikelboom\u00a0J, Oldgren\u00a0J, Parekh\u00a0A et\u00a0al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"788_CR27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1177\/1747493016681019","volume":"12","author":"T Geisler","year":"2017","unstructured":"Geisler\u00a0T, Poli\u00a0S, Meisner\u00a0C, Schreieck\u00a0J, Zuern\u00a0CS, Nagele\u00a0T et\u00a0al (2017) Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 12:985\u2013990","journal-title":"Int J Stroke"},{"key":"788_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/1747493018799981","volume":"14","author":"H Kamel","year":"2019","unstructured":"Kamel\u00a0H, Longstreth\u00a0WT Jr., Tirschwell\u00a0DL, Kronmal\u00a0RA, Broderick\u00a0JP, Palesch\u00a0YY et\u00a0al (2019) The atRial ardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke 14:207\u2013214","journal-title":"Int J Stroke"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-00788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T23:42:58Z","timestamp":1601077378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-00788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-00788-w","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"27 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0K\u00f6hrmann und C.\u00a0Kleinschnitz geben an von Boehringer Ingelheim, Bayer, BMS\/Pfizer, Daiichi, Stryker, Medtronic, Biogen und Novartis Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit erhalten zu haben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}